RVMD
NASDAQRevolution Medicines Inc.
Price$191.21-1.53 (-0.79%)
01:30 PM07:45 PM
News · 26 weeks99+420%
2026-01-112026-07-05
Mix5890d
- Insider19(33%)
- SEC Filings18(31%)
- Other13(22%)
- Offering3(5%)
- Earnings3(5%)
- Analyst2(3%)
Latest news
25 items- PREuropean Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review ProcessPhased review by EMA aims to accelerate assessment of company's investigational drug daraxonrasib in pancreatic cancer based on unprecedented clinical results from pivotal Phase 3 RASolute 302 trial Rolling submission of NDA for daraxonrasib to U.S. FDA under Commissioner’s National Priority Voucher pilot program nearing completion REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a phased review of data on daraxon
- PRRevolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 clinical trials evaluating zoldonrasib, its oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for patients with RAS G12D metastatic pancreatic ductal adenocarcinoma (PDAC). The results, which will be presented today in a proffered paper session at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, include zoldonrasib in combination with standard of care chemotherapy in previously untre
- INSIDERDirector Patel Sushil exercised 2,955 shares at a strike of $37.54 and sold $1,048,967 worth of shares (5,580 units at $187.99) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 21,656 units (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDERChief Financial Officer Anders Jack exercised 20,000 shares at a strike of $18.56 and sold $3,366,604 worth of shares (20,000 units at $168.33) as part of a pre-agreed trading plan (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- PRRevolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026REDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that four oral and poster presentations highlighting data from its RAS(ON) pipeline will be featured at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, taking place July 1–4, 2026 in Munich, Germany. The program will include two oral presentations from Phase 1/2 trials evaluating zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for patients with metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC). These
- INSIDERDirector Kim Lorence H. was granted 1,191 shares, increasing direct ownership by 2% to 74,281 units (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDERDirector Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDERDirector Anderson Elizabeth M was granted 1,191 shares, increasing direct ownership by 14% to 9,406 units (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDERDirector Horning Sandra was granted 1,191 shares, increasing direct ownership by 1% to 97,765 units (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDERDirector Clyburn Frank was granted 1,191 shares, increasing direct ownership by 12% to 10,929 units (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDERDirector Patel Sushil was granted 1,191 shares, increasing direct ownership by 5% to 24,281 units (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDERDirector Borellini Flavia was granted 1,191 shares, increasing direct ownership by 5% to 26,215 units (SEC Form 4)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- PRRevolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic CancerREDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 305, a global, randomized Phase 3 clinical trial evaluating zoldonrasib in combination with standard of care chemotherapy as a first line treatment in patients with metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC). "Pancreatic cancer is a RAS-driven disease, and we recently reported that daraxonrasib, our RAS(ON) multi-selective inhibitor, significantly improved overall survival, progression-free survival, response rates, and prese
- SECSEC Form 8-K filed by Revolution Medicines Inc.8-K - Revolution Medicines, Inc. (0001628171) (Filer)
- PRRevolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strategy REDWOOD CITY, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Steve Kelsey, M.D., FRCP, FRCPath, president, research and development, will transition into the role of senior advisor to the chief executive officer, effective July 1, 2026. Dr. Kelsey plans to retire from his employment with the company on January 4, 2027, at wh
- INSIDEROfficer Mancini Anthony sold $720,490 worth of shares (4,615 units at $156.12), decreasing direct ownership by 8% to 49,975 units (SEC Form 4) to satisfy withholding tax4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDEROfficer Goldsmith Mark A sold $1,564,310 worth of shares (10,020 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 267,330 units (SEC Form 4) to satisfy withholding tax4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDERGeneral Counsel Cislini Jeff sold $336,749 worth of shares (2,157 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 56,521 units (SEC Form 4) (for tax liability)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDERChief Financial Officer Anders Jack sold $424,956 worth of shares (2,722 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,269 units (SEC Form 4) to satisfy withholding tax4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDEROfficer Kelsey Stephen Michael sold $651,798 worth of shares (4,175 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 291,876 units (SEC Form 4) (withholding tax)4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- INSIDERChief Operating Officer Horn Margaret A exercised 90,000 shares at a strike of $30.82 and sold $14,972,110 worth of shares (93,575 units at $160.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 154,647 units (SEC Form 4) to cover taxes4 - Revolution Medicines, Inc. (0001628171) (Issuer)
- SECSEC Form 144 filed by Revolution Medicines Inc.144 - Revolution Medicines, Inc. (0001628171) (Subject)
- SECSEC Form 144 filed by Revolution Medicines Inc.144 - Revolution Medicines, Inc. (0001628171) (Subject)
- SECSEC Form 144 filed by Revolution Medicines Inc.144 - Revolution Medicines, Inc. (0001628171) (Subject)
- SECSEC Form 144 filed by Revolution Medicines Inc.144 - Revolution Medicines, Inc. (0001628171) (Subject)
RVMD FAQ
7 questionsWhat does Revolution Medicines Inc. do?
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a...Where does RVMD stock trade?
Revolution Medicines Inc. (RVMD) is listed on NASDAQ.What sector and industry is RVMD in?
Revolution Medicines Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Revolution Medicines Inc. go public?
Revolution Medicines Inc. (RVMD) completed its IPO in 2020.What are analysts saying about RVMD?
Revolution Medicines Inc. has had 8 recent analyst actions on file. The most recent action was from Bernstein: Mkt Perform on 2026-05-22.What companies are similar to RVMD?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), BIIB (Biogen Inc.). Compare RVMD side-by-side with any of them on Quantisnow.How can I track RVMD on Quantisnow?
Quantisnow aggregates Revolution Medicines Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RVMD to receive live email and push alerts on every new disclosure.